• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于移行带的前列腺特异性抗原密度用于鉴别PI-RADS 3分病变中具有临床意义的前列腺癌

Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.

作者信息

Jin Yongming, Chen Fei, Xu Gang, Wei Chaogang, Dong Congsong

机构信息

Department of Radiology, The Yancheng School of Clinical Medicine of Nanjing Medical University, Yancheng Third People's Hospital, Yancheng, China.

Department of Radiology, Second Affiliated Hospital of Soochow University, Suzhou, China.

出版信息

Sci Rep. 2025 Jan 25;15(1):3258. doi: 10.1038/s41598-025-87311-1.

DOI:10.1038/s41598-025-87311-1
PMID:39863696
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11762996/
Abstract

We intended to investigate the potential of several transitional zone (TZ) volume-related variables for the detection of clinically significant prostate cancer (csPCa) among lesions scored as Prostate Imaging Reporting and Data System (PI-RADS) category 3. Between September 2018 and August 2023, patients who underwent mpMRI examination and scored as PI-RADS 3 were queried from our institution. The diagnostic performances of prostate-specific antigen density (PSAD), TZ-adjusted PSAD (TZPSAD), and TZ-ratio (TZ volume/whole gland prostate volume) were analyzed. We calculated the sensitivity and specificity for each variable, the overall accuracy was evaluated with the area under the receiver operating characteristic curve (AUC). The best cutoff value was determined by the Youden index, and differences between diagnostic performances were compared with the Delong test. A total of 154 TZ lesions were included, of them 28 were diagnosed with csPCa. The AUC for PSAD, TZPSAD, and TZ-ratio were 0.644 (95% CI 0.538-0.751), 0.714 (95% CI 0.607-0.821), and 0.746 (95% CI 0.636-0.856), with corresponding optimal cutoff values of 0.11 ng/ml/ml, 0.21 ng/ml/ml, and 0.66 ng/ml/ml, respectively. PSAD was significantly inferior to either TZPSAD (P = 0.03) or TZ-ratio (P = 0.03). The combination model including TZPSAD, TZ-ratio, and age generated an AUC of 0.838 (95% CI 0.759-0.917), significantly higher than use of these variables alone, with P values of 0.001 and 0.035 for the TZPSAD and TZ-ratio, respectively. TZPSAD and TZ-ratio were found to be independent predictors for differentiating csPCa among TZ lesions categorized as PI-RADS score 3. Furthermore, by combining these two variables with others, the diagnostic performance can be improved significantly.

摘要

我们旨在研究几个与移行区(TZ)体积相关的变量在检测前列腺影像报告和数据系统(PI-RADS)分类为3类的病变中具有临床意义的前列腺癌(csPCa)的潜力。在2018年9月至2023年8月期间,从我们机构查询接受多参数磁共振成像(mpMRI)检查且PI-RADS评分为3分的患者。分析了前列腺特异性抗原密度(PSAD)、经TZ校正的PSAD(TZPSAD)和TZ比值(TZ体积/前列腺总体积)的诊断性能。我们计算了每个变量的敏感性和特异性,通过受试者工作特征曲线下面积(AUC)评估总体准确性。通过约登指数确定最佳临界值,并使用德龙检验比较诊断性能之间的差异。共纳入154个TZ病变,其中28个被诊断为csPCa。PSAD、TZPSAD和TZ比值的AUC分别为0.644(95%CI 0.538 - 0.751)、0.714(95%CI 0.607 - 0.821)和0.746(95%CI 0.636 - 0.856),相应的最佳临界值分别为0.11 ng/ml/ml、0.21 ng/ml/ml和0.66 ng/ml/ml。PSAD明显低于TZPSAD(P = 0.03)或TZ比值(P = 0.03)。包括TZPSAD、TZ比值和年龄的联合模型产生的AUC为0.838(95%CI 0.759 - 0.917),显著高于单独使用这些变量,TZPSAD和TZ比值的P值分别为0.001和0.035。发现TZPSAD和TZ比值是区分PI-RADS评分为3分的TZ病变中csPCa的独立预测因素。此外,通过将这两个变量与其他变量相结合,诊断性能可显著提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/f57796ebcef4/41598_2025_87311_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/2ff4983e5e20/41598_2025_87311_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/859909480e4c/41598_2025_87311_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/f57796ebcef4/41598_2025_87311_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/2ff4983e5e20/41598_2025_87311_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/859909480e4c/41598_2025_87311_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dfe0/11762996/f57796ebcef4/41598_2025_87311_Fig3_HTML.jpg

相似文献

1
Transition zone-based prostate-specific antigen density for differentiating clinically significant prostate cancer in PI-RADS score 3 lesions.基于移行带的前列腺特异性抗原密度用于鉴别PI-RADS 3分病变中具有临床意义的前列腺癌
Sci Rep. 2025 Jan 25;15(1):3258. doi: 10.1038/s41598-025-87311-1.
2
Prospective evaluation of mpMRI-derived nomograms for detecting prostate cancer in PI-RADS v2.1 upgraded and non-upgraded lesions.基于多参数磁共振成像(mpMRI)的列线图对PI-RADS v2.1升级和未升级病变中前列腺癌检测的前瞻性评估
Front Oncol. 2025 Jun 4;15:1510049. doi: 10.3389/fonc.2025.1510049. eCollection 2025.
3
Deep learning-assisted prostate cancer detection on bi-parametric MRI: minimum training data size requirements and effect of prior knowledge.深度学习辅助双参数 MRI 前列腺癌检测:最小训练数据量要求及先验知识的影响。
Eur Radiol. 2022 Apr;32(4):2224-2234. doi: 10.1007/s00330-021-08320-y. Epub 2021 Nov 16.
4
Assessing the Impact of Transition and Peripheral Zone PSA Densities Over Whole-Gland PSA Density for Prostate Cancer Detection on Multiparametric MRI.评估移行区和外周带前列腺特异性抗原(PSA)密度相对于全腺PSA密度对多参数磁共振成像检测前列腺癌的影响。
Prostate. 2025 May;85(6):612-624. doi: 10.1002/pros.24863. Epub 2025 Feb 25.
5
MRI-based risk stratification for clinically significant prostate cancer detection at biopsy: The value of zonal-specific PSA density and PSHS.基于磁共振成像的活检时临床显著前列腺癌检测的风险分层:区域特异性前列腺特异性抗原密度和前列腺影像报告和数据系统的价值
Eur J Radiol. 2025 Mar;184:111982. doi: 10.1016/j.ejrad.2025.111982. Epub 2025 Feb 4.
6
Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score.在前列腺特异性抗原和 PI-RADS≥3 病变的前列腺多参数磁共振成像中前列腺特异性抗原升高的男性中选择前列腺活检候选者时前列腺特异性抗原密度的附加价值:按 PI-RADS 评分进行系统评估。
Eur Urol Focus. 2024 Jul;10(4):634-640. doi: 10.1016/j.euf.2023.10.006. Epub 2023 Oct 19.
7
The Role of PSA Density among PI-RADS v2.1 Categories to Avoid an Unnecessary Transition Zone Biopsy in Patients with PSA 4-20 ng/mL.前列腺特异性抗原密度在PI-RADS v2.1分类中对避免血清前列腺特异性抗原水平为4-20 ng/mL患者进行不必要的移行带活检的作用。
Biomed Res Int. 2021 Oct 11;2021:3995789. doi: 10.1155/2021/3995789. eCollection 2021.
8
Reduction of false positives using zone-specific prostate-specific antigen density for prostate MRI-based biopsy decision strategies.基于 MRI 的前列腺活检决策策略中,使用区域特异性前列腺特异性抗原密度降低假阳性率。
Eur Radiol. 2024 Oct;34(10):6229-6240. doi: 10.1007/s00330-024-10700-z. Epub 2024 Mar 28.
9
Transition-zone PSA-density calculated from MRI deep learning prostate zonal segmentation model for prediction of clinically significant prostate cancer.基于MRI深度学习前列腺分区分割模型计算的移行区前列腺特异抗原密度,用于预测临床显著性前列腺癌。
Abdom Radiol (NY). 2024 Oct;49(10):3722-3734. doi: 10.1007/s00261-024-04301-z. Epub 2024 Jun 19.
10
Unlocking Precision Enhancing Prostate Cancer Detection and Reducing Unnecessary Biopsies with Combined Prostate-Specific Antigen Density and PI-RADS Score.结合前列腺特异性抗原密度和 PI-RADS 评分提高前列腺癌检测的精准度,减少不必要的活检。
J Coll Physicians Surg Pak. 2024 Oct;34(10):1205-1210. doi: 10.29271/jcpsp.2024.10.1205.

本文引用的文献

1
A novel clinically significant prostate cancer prediction system with multiparametric MRI and PSA: P.Z.A. score.一种基于多参数 MRI 和 PSA 的新型具有临床意义的前列腺癌预测系统:P.Z.A.评分。
BMC Cancer. 2023 Nov 23;23(1):1138. doi: 10.1186/s12885-023-11306-2.
2
Diagnostic Performance of Prostate-specific Antigen Density for Detecting Clinically Significant Prostate Cancer in the Era of Magnetic Resonance Imaging: A Systematic Review and Meta-analysis.基于磁共振成像时代下前列腺特异性抗原密度对临床显著前列腺癌的诊断性能:系统评价和荟萃分析。
Eur Urol Oncol. 2024 Apr;7(2):189-203. doi: 10.1016/j.euo.2023.08.002. Epub 2023 Aug 26.
3
Screening for Prostate Cancer.
前列腺癌筛查
N Engl J Med. 2023 Apr 13;388(15):1405-1414. doi: 10.1056/NEJMcp2209151.
4
New model of PIRADS and adjusted prostatespecific antigen density of peripheral zone improves the detection rate of initial prostate biopsy: a diagnostic study.新型 PIRADS 模型和外周带前列腺特异性抗原密度校正可提高初始前列腺活检的检出率:一项诊断研究。
Asian J Androl. 2023 Jan-Feb;25(1):126-131. doi: 10.4103/aja202218.
5
Prostate cancer.前列腺癌。
Lancet. 2021 Sep 18;398(10305):1075-1090. doi: 10.1016/S0140-6736(21)00950-8. Epub 2021 Aug 6.
6
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.《全球癌症统计数据 2020:全球 185 个国家和地区 36 种癌症的发病率和死亡率估计》。
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
7
Zonal adjusted PSA density improves prostate cancer detection rates compared with PSA in Taiwanese males with PSA < 20 ng/ml.与 PSA 相比,在 PSA<20ng/ml 的台湾男性中,分区调整 PSA 密度可提高前列腺癌的检出率。
BMC Urol. 2020 Oct 7;20(1):151. doi: 10.1186/s12894-020-00717-z.
8
Clinical utility of PSAD combined with PI-RADS category for the detection of clinically significant prostate cancer.前列腺特异抗原密度(PSAD)联合前列腺影像报告和数据系统(PI-RADS)分类在检测临床显著性前列腺癌中的临床应用
Urol Oncol. 2020 Nov;38(11):846.e9-846.e16. doi: 10.1016/j.urolonc.2020.05.024. Epub 2020 Jun 21.
9
The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies.前列腺特异性抗原密度对多参数磁共振成像上前列腺影像报告和数据系统3类病变的价值:一种避免不必要前列腺活检的策略
Eur Urol Focus. 2021 Mar;7(2):325-331. doi: 10.1016/j.euf.2019.11.012. Epub 2019 Dec 12.
10
Comparison of PSA-density of the transition zone and whole gland for risk stratification of men with suspected prostate cancer: A retrospective MRI-cohort study.比较可疑前列腺癌患者的移行区和整个腺体的 PSA 密度,以进行风险分层:一项回顾性 MRI 队列研究。
Eur J Radiol. 2019 Nov;120:108660. doi: 10.1016/j.ejrad.2019.108660. Epub 2019 Sep 7.